Resumen:
Overactive bladder (OAB) is a pathology impairing patients’ quality of life and with a high percentage of patients who are refractory to medication. In this paper, technical opinion of an «expert panel» is assessed in order to gain the most reliable professional consensus on scientific evidence available on the criteria for the use of Onabotulinumtoxin A (OnabotA) in OAB.